Full Text:   <1167>

CLC number: R730.51

On-line Access: 2019-05-15

Received: 2019-03-29

Revision Accepted: 2019-04-05

Crosschecked: 2019-04-17

Cited: 0

Clicked: 2115

Citations:  Bibtex RefMan EndNote GB/T7714

-   Go to

Article info.
Open peer comments

Journal of Zhejiang University SCIENCE B 2019 Vol.20 No.5 P.373-380

http://doi.org/10.1631/jzus.B1900204


Tumor immunology and immunotherapy: a journey I started from Hangzhou


Author(s):  Gen-Sheng Feng

Affiliation(s):  Department of Pathology, School of Medicine; more

Corresponding email(s):   gfeng@ucsd.edu

Key Words:  Immunotherapy, Liver cancer, Tumor immunology, 90th Anniversary


Gen-Sheng Feng. Tumor immunology and immunotherapy: a journey I started from Hangzhou[J]. Journal of Zhejiang University Science B, 2019, 20(5): 373-380.

@article{title="Tumor immunology and immunotherapy: a journey I started from Hangzhou",
author="Gen-Sheng Feng",
journal="Journal of Zhejiang University Science B",
volume="20",
number="5",
pages="373-380",
year="2019",
publisher="Zhejiang University Press & Springer",
doi="10.1631/jzus.B1900204"
}

%0 Journal Article
%T Tumor immunology and immunotherapy: a journey I started from Hangzhou
%A Gen-Sheng Feng
%J Journal of Zhejiang University SCIENCE B
%V 20
%N 5
%P 373-380
%@ 1673-1581
%D 2019
%I Zhejiang University Press & Springer
%DOI 10.1631/jzus.B1900204

TY - JOUR
T1 - Tumor immunology and immunotherapy: a journey I started from Hangzhou
A1 - Gen-Sheng Feng
J0 - Journal of Zhejiang University Science B
VL - 20
IS - 5
SP - 373
EP - 380
%@ 1673-1581
Y1 - 2019
PB - Zhejiang University Press & Springer
ER -
DOI - 10.1631/jzus.B1900204


Abstract: 
This short article is dedicated to the 90th Anniversary of the School of Life Sciences at Zhejiang University, China. immunotherapy of cancer is currently a hot topic in the biomedical field, and a re-search focus of my laboratory is on developing new and effective combinatorial immunotherapeutic strategies for liver cancer. Of note, my interest in immunotherapy of cancer stems from the training as an undergraduate student at Hangzhou University, China, almost 40 years ago.

肿瘤免疫学和免疫治疗:我的旅程从杭州出发

概要:为庆祝浙江大学生命科学学院九十华诞,谨写此文.作者冯根生是原杭州大学生物学系七七级学生;在杭大求学期间,选修了免疫学和肿瘤生物学,深受启发.冯现在是加州大学圣地亚哥校区医学院病理系和生命科学学院的教授.实验室目前的研究重点是肝癌发病机理和肝癌免疫治疗.这得益于当年在杭大的启蒙教育.
关键词:肝癌免疫治疗;肿瘤免疫学;浙大生科院九十华诞

Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article

Reference

[1]Bard-Chapeau EA, Yuan J, Droin N, et al., 2006. Concerted functions of Gab1 and Shp2 in liver regeneration and hepatoprotection. Mol Cell Biol, 26(12):4664-4674.

[2]Bard-Chapeau EA, Li SW, Ding J, et al., 2011. Ptpn11/Shp2 acts as a tumor suppressor in hepatocellular carcinogenesis. Cancer Cell, 19(5):629-639.

[3]Chan RJ, Feng GS, 2007. PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase. Blood, 109(3):862-867.

[4]Darnell JE Jr, Kerr IM, Stark GR, 1994. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science, 264(5164):1415-1421.

[5]Ding RR, Ma ZZ, Zhang TW, et al., 1984. Studies on the cytolytic effect of SeO2 on the Ehrlich ascites tumor cells. J Hangzhou Univ, 11(2):269-271 (in Chinese).

[6]Feng GS, 2012. Conflicting roles of molecules in hepatocarcinogenesis: paradigm or paradox. Cancer Cell, 21(2):150-154.

[7]Feng GS, Taylor MW, 1989. Interferon γ-resistant mutants are defective in the induction of indoleamine 2,3-dioxygenase. Proc Natl Acad Sci USA, 86(18):7144-7148.

[8]Feng GS, Pawson T, 1994. Phosphotyrosine phosphatases with SH2 domains: regulators of signal transduction. Trends Genet, 10(2):54-58.

[9]Feng GS, Ye TX, Yang SK, 1985. Purification and characterization of human interferon-γ, Part I. Shanghai J Immunol, 5(6):335-338 (in Chinese).

[10]Feng GS, Ye TX, Yang SK, 1986. Purification and characterization of human interferon-γ. II. Further purification and studies on physicochemical properties. Chin J Microbiol Immunol, 6(2):103-106 (in Chinese).

[11]Feng GS, Gray PW, Shepard HM, et al., 1988. Antiproliferative activity of a hybrid protein between interferon-γ and tumor necrosis factor-β. Science, 241(4872):1501-1503.

[12]Feng GS, Chong K, Kumar A, et al., 1992. Identification of double-stranded RNA-binding domains in the interferon-induced double-stranded RNA-activated p68 kinase. Proc Natl Acad Sci USA, 89(12):5447-5451.

[13]Feng GS, Hui CC, Pawson T, 1993. SH2-containing phosphotyrosine phosphatase as a target of protein-tyrosine kinases. Science, 259(5101):1607-1611.

[14]Koch CA, Anderson D, Moran MF, et al., 1991. SH2 and SH3 domains: elements that control interactions of cytoplasmic signaling proteins. Science, 252(5006):668-674.

[15]Lee J, Liao R, Wang GW, et al., 2017. Preventive inhibition of liver tumorigenesis by systemic activation of innate immune functions. Cell Rep, 21(7):1870-1882.

[16]Ma ZZ, Zhe SJ, Ding RR, et al., 1984. The Effect of SeO2 on immune function in Ehrlich ascites tumor-bearing mice. J Hangzhou Univ, 11(2):241-245 (in Chinese).

[17]Meurs E, Chong K, Galabru J, et al., 1990. Molecular cloning and characterization of the human double-stranded RNA-activated protein kinase induced by interferon. Cell, 62(2):379-390.

[18]Qu CK, Shi ZQ, Shen R, et al., 1997. A deletion mutation in the SH2-N domain of Shp-2 severely suppresses hematopoietic cell development. Mol Cell Biol, 17(9):5499-5507.

[19]Qu CK, Yu WM, Azzarelli B, et al., 1998. Biased suppression of hematopoiesis and multiple developmental defects in chimeric mice containing Shp-2 mutant cells. Mol Cell Biol, 18(10):6075-6082.

[20]Qu CK, Nguyen S, Chen JZ, et al., 2001. Requirement of Shp-2 tyrosine phosphatase in lymphoid and hematopoietic cell development. Blood, 97(4):911-914.

[21]Velazquez L, Fellous M, Stark G R, et al., 1992. A protein tyrosine kinase in the interferon αβ signaling pathway. Cell, 70(2):313-322.

[22]Wen L, Xin B, Wu P, et al., 2019. An efficient combination immunotherapy for primary liver cancer by harmonized activation of innate and adaptive immunity in mice. Hepatology, online version of record.

[23]Zhu HH, Luo X, Zhang K, et al., 2015. Shp2 and Pten have antagonistic roles in myeloproliferation but cooperate to promote erythropoiesis in mammals. Proc Natl Acad Sci USA, 112(43):13342-13347.

Open peer comments: Debate/Discuss/Question/Opinion

<1>

Please provide your name, email address and a comment





Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou 310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn
Copyright © 2000 - 2022 Journal of Zhejiang University-SCIENCE